What's Happening?
10x Genomics, a leader in single cell and spatial biology, announced its financial results for the fourth quarter and full year of 2025, along with its outlook for 2026. The company reported a revenue of $166 million for the fourth quarter, a 1% increase from the previous year, and a full-year revenue of $642.8 million. Excluding non-recurring revenue from patent litigation settlements, the full-year revenue was $598.7 million, a 2% decrease from 2024. The company highlighted strategic partnerships with the Cancer Research Institute and PharosAI to develop AI-ready datasets for cancer research. Additionally, collaborations with Dana-Farber Cancer Institute and Brigham & Women's Hospital aim to enhance cancer diagnostics and autoimmune disease
research. The company ended the year with $523.4 million in cash and marketable securities, an increase of $130 million from the previous year.
Why It's Important?
10x Genomics' financial performance and strategic initiatives are crucial as they reflect the company's position in the rapidly evolving field of biotechnology. The partnerships with leading research institutions underscore the company's commitment to advancing cancer research and diagnostics through innovative technologies. The focus on AI-driven demand and translational research positions 10x Genomics to capitalize on emerging clinical opportunities. The company's strong cash position provides a solid foundation for continued investment in research and development, supporting its long-term growth strategy. The financial results also highlight the challenges faced by the company, such as decreased revenue excluding litigation settlements, emphasizing the need for strategic innovation and partnerships.
What's Next?
For 2026, 10x Genomics expects revenue to range between $600 million and $625 million, representing up to 4% growth over 2025, excluding non-recurring revenue. The company plans to continue expanding its impact through new product innovations and strategic partnerships. The focus on AI-driven research and emerging clinical opportunities is expected to drive growth across multiple business vectors. The company will host a conference call to discuss its financial results and business developments, providing further insights into its strategic direction. The ongoing collaborations with research institutions are likely to yield significant advancements in cancer and autoimmune disease research, enhancing the company's market position.
